Mereo BioPharma Group plc
MREO
$2.17
-$0.08-3.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 53.17% | -19.25% | -43.97% | 22.65% | -129.69% |
| Total Depreciation and Amortization | -103.90% | 15.95% | -1.82% | -2.49% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -107.86% | 208.42% | 119.17% | -184.62% | 3,399.62% |
| Change in Net Operating Assets | 128.96% | -150.75% | 65.87% | 140.75% | -115.06% |
| Cash from Operations | 2.79% | 3.20% | -4.23% | -38.75% | -382.78% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | 57.14% | -- | -- |
| Cash from Investing | -- | -100.00% | 54.29% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 38.81% | -- | -- | -16.24% |
| Cash from Financing | 100.00% | -100.29% | -- | -- | -107.51% |
| Foreign Exchange rate Adjustments | -134.72% | 1,433.64% | 1,397.14% | -174.91% | 220.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.50% | -116.40% | 16.46% | -109.87% | -172.25% |